- Home
- ITIC vs SLRX Comparison
ITIC vs SLRX Comparison
Compare ITIC & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | SLRX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.1M | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITIC | SLRX |
|---|---|---|
| Price | $252.19 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 309.0K |
| Earning Date | 02-12-2026 | 11-14-2025 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 19.00 | N/A |
| Revenue | ★ $273,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.18 | ★ N/A |
| Revenue Growth | ★ 13.63 | N/A |
| 52 Week Low | $190.20 | $0.62 |
| 52 Week High | $288.98 | $108.00 |
Technical Indicators
Market Signals| Indicator | ITIC | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 25.62 |
| Support Level | $248.73 | $0.62 |
| Resistance Level | $254.14 | $0.72 |
| Average True Range (ATR) | 6.31 | 0.06 |
| MACD | 0.49 | 0.07 |
| Stochastic Oscillator | 65.41 | 8.21 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.